Cancer as a robust system: implications for anticancer therapy

Cancers are extremely complex, heterogeneous diseases. Many approaches to anticancer treatment have had limited success — cures are still rare. A fundamental hurdle to cancer therapy is acquired tumour 'robustness'. The goal of this article is to present a perspective on cancer as a robust system to provide a framework from which the complexity of tumours can be approached to yield novel therapies.

[1]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[2]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[3]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[4]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[5]  V. Ling,et al.  Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[7]  J. F. Harris,et al.  Dynamic heterogeneity and metastasis , 1984, Journal of cellular physiology. Supplement.

[8]  H. Skipper,et al.  Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. , 1984, Cancer treatment reports.

[9]  Skipper He,et al.  Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. , 1984 .

[10]  V. Ling,et al.  Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. , 1984, Science.

[11]  P. Nowell Mechanisms of tumor progression. , 1986, Cancer research.

[12]  [Chronobiology and cancer]. , 1987, Pathologie-biologie.

[13]  V. Ling,et al.  Dynamic heterogeneity: characterization of two cell lines derived from experimental lung metastases of mouse KHT fibrosarcoma. , 1987, Invasion & metastasis.

[14]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[15]  C. Seynaeve,et al.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. , 1991, British Journal of Cancer.

[16]  C. Seynaeve,et al.  Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer , 1991 .

[17]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[18]  Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Schornagel,et al.  Clinical pharmacokinetics of anti-metabolites. , 1993, Cancer surveys.

[20]  M. Eigen Viral quasi species. , 1993 .

[21]  M. Eigen,et al.  Viral quasispecies. , 1993, Scientific American.

[22]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[23]  C. Murray Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.

[24]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[25]  M. Goldberg,et al.  Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.

[26]  A. Giaccia,et al.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.

[27]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[28]  P. Sismondi,et al.  Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA). , 1997, Cancer investigation.

[29]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[30]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[31]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[32]  M. Bader,et al.  Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85). , 1997, British Journal of Cancer.

[33]  A. Arkin,et al.  Stochastic mechanisms in gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Risau,et al.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.

[35]  A. Arkin,et al.  Simulation of prokaryotic genetic circuits. , 1998, Annual review of biophysics and biomolecular structure.

[36]  A. Andrén-sandberg,et al.  Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations , 1998, Genes, chromosomes & cancer.

[37]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[38]  S. Kaye Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. , 1998, Current opinion in oncology.

[39]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[40]  M. B,et al.  Bifurcation Analysis of a Model of Mitotic Control in Frog Eggs , 1998 .

[41]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[42]  J. W. Little,et al.  Robustness of a gene regulatory circuit , 1999, The EMBO journal.

[43]  A. Arkin,et al.  It's a noisy business! Genetic regulation at the nanomolar scale. , 1999, Trends in genetics : TIG.

[44]  U. Alon,et al.  Robustness in bacterial chemotaxis , 2022 .

[45]  J M Carlson,et al.  Highly optimized tolerance: a mechanism for power laws in designed systems. , 1999, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[46]  L. Ossowski,et al.  Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.

[47]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[48]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.

[49]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[50]  I. Weinstein Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. , 2000, Carcinogenesis.

[51]  L. Guarente,et al.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.

[52]  U Alon,et al.  Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Odell,et al.  The segment polarity network is a robust developmental module , 2000, Nature.

[54]  Hui Wang,et al.  MDM2 oncogene as a novel target for human cancer therapy. , 2000, Current pharmaceutical design.

[55]  Albert-László Barabási,et al.  Error and attack tolerance of complex networks , 2000, Nature.

[56]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[57]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[58]  R. Albert,et al.  The large-scale organization of metabolic networks , 2000, Nature.

[59]  L. Guarente,et al.  Sir2 links chromatin silencing, metabolism, and aging. , 2000, Genes & development.

[60]  P. Duesberg,et al.  Aneuploidy, the somatic mutation that makes cancer a species of its own. , 2000, Cell motility and the cytoskeleton.

[61]  P. Duesberg,et al.  Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Doyle,et al.  Robust perfect adaptation in bacterial chemotaxis through integral feedback control. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  G. Naumov,et al.  Solitary cancer cells as a possible source of tumour dormancy? , 2001, Seminars in cancer biology.

[64]  M J Bissell,et al.  Tumors are unique organs defined by abnormal signaling and context. , 2001, Seminars in cancer biology.

[65]  A. Andrén-sandberg,et al.  Extensive cytogenetic heterogeneity in a benign retroperitoneal schwannoma. , 2001, Cancer genetics and cytogenetics.

[66]  V. Schirrmacher T-cell immunity in the induction and maintenance of a tumour dormant state. , 2001, Seminars in cancer biology.

[67]  A. Levine,et al.  The p53 functional circuit. , 2001, Journal of cell science.

[68]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[69]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[70]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  W. Falk,et al.  A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. , 2001, Cancer research.

[72]  H. Kitano,et al.  Robust oscillations within the interlocked feedback model of Drosophila circadian rhythm. , 2001, Journal of theoretical biology.

[73]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[74]  M. Blagosklonny,et al.  Exploiting cancer cell cycling for selective protection of normal cells. , 2001, Cancer research.

[75]  L. Mayer,et al.  Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. , 2001, Current medicinal chemistry. Anti-cancer agents.

[76]  P Vaupel,et al.  Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.

[77]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[78]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[79]  J. Aguirre-Ghiso,et al.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.

[80]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[81]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[82]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[83]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[84]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[86]  A. Zlotnik,et al.  Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.

[87]  R. Solé,et al.  Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Drevs,et al.  Antiangiogenesis: Current Clinical Data and Future Perspectives , 2002, Oncology Research and Treatment.

[89]  Manfred Eigen,et al.  Error catastrophe and antiviral strategy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[90]  P. Nowell Tumor progression: a brief historical perspective. , 2002, Seminars in cancer biology.

[91]  Jeff Hasty,et al.  Engineered gene circuits , 2002, Nature.

[92]  C. Rao,et al.  Control, exploitation and tolerance of intracellular noise , 2002, Nature.

[93]  Pablo A. Parrilo,et al.  Introducing SOSTOOLS: a general purpose sum of squares programming solver , 2002, Proceedings of the 41st IEEE Conference on Decision and Control, 2002..

[94]  G. Odell,et al.  Robustness, Flexibility, and the Role of Lateral Inhibition in the Neurogenic Network , 2002, Current Biology.

[95]  J. Doyle,et al.  Robustness as a measure of plausibility in models of biochemical networks. , 2002, Journal of theoretical biology.

[96]  A. Harris,et al.  Hypoxia‐induced pathways in breast cancer , 2002, Microscopy research and technique.

[97]  P. Klatt,et al.  'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally , 2002, The EMBO journal.

[98]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[99]  H. Kitano Systems Biology: A Brief Overview , 2002, Science.

[100]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[101]  D. Rasnick Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. , 2002, Cancer genetics and cytogenetics.

[102]  Jeffrey S. Smith Human Sir2 and the 'silencing' of p53 activity. , 2002, Trends in cell biology.

[103]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[104]  Hiroaki Kitano,et al.  Cancer robustness: Tumour tactics , 2003, Nature.

[105]  C. Parish Cancer immunotherapy: The past, the present and the future , 2003, Immunology and cell biology.

[106]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[107]  A. Hochhaus Cytogenetic and molecular mechanisms of resistance to imatinib. , 2003, Seminars in hematology.

[108]  D. Berrigan,et al.  Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. , 2003, Annual review of medicine.

[109]  L. Guarente,et al.  How does calorie restriction work? , 2003, Genes & development.

[110]  E. Eigenbrodt,et al.  The tumor metabolome. , 2003, Anticancer research.

[111]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[112]  P. Carli,et al.  Immediate local and regional recurrence after the excision of a polypoid melanoma: tumor dormancy or tumor activation? , 2003, Dermatologic Surgery.

[113]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[114]  J. Tischfield,et al.  Somatic recombination redux , 2003, Nature Genetics.

[115]  J. Aguirre-Ghiso,et al.  ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.

[116]  Mina J Bissell,et al.  Tumor reversion: Correction of malignant behavior by microenvironmental cues , 2003, International journal of cancer.

[117]  A. Papachristodoulou,et al.  Analysis of switched and hybrid systems - beyond piecewise quadratic methods , 2003, Proceedings of the 2003 American Control Conference, 2003..

[118]  M. Hiraoka,et al.  Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.

[119]  J. Aguirre-Ghiso,et al.  ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .

[120]  Ricard V. Solé,et al.  Phase transitions in unstable cancer cell populations , 2003 .

[121]  J. Denu Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. , 2003, Trends in biochemical sciences.

[122]  Mattias Höglund,et al.  Power law distribution of chromosome aberrations in cancer. , 2003, Cancer research.

[123]  Giuseppe Tonini,et al.  Cancer chronotherapy: Principles, applications, and perspectives , 2003, Cancer.

[124]  D. Lane,et al.  The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. , 2003, Mini reviews in medicinal chemistry.

[125]  K. Haigis,et al.  A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity , 2003, Nature Genetics.

[126]  L. Ellis,et al.  Promises and pitfalls of anti-angiogenic therapy in clinical trials. , 2003, Trends in molecular medicine.

[127]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[128]  M. Feuerer,et al.  T Cell Memory, Anergy and Immunotherapy in Breast Cancer , 2002, Journal of Mammary Gland Biology and Neoplasia.

[129]  J. Spalding,et al.  Toward a chronotherapy of neoplasia: Tolerance of treatment depends upon host rhythms , 1973, Experientia.

[130]  M. Falk Human Sir 2 and the ‘ silencing ’ of p 53 activity , 2022 .

[131]  R. Huber,et al.  Transcriptional silencing and longevity protein Sir 2 is an NAD-dependent histone deacetylase , 2022 .